Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.
Related Items
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
Last modified: April 27, 2020